203 related articles for article (PubMed ID: 8912843)
1. Sequences within the first exon of BCR inhibit the activated tyrosine kinases of c-Abl and the Bcr-Abl oncoprotein.
Liu J; Wu Y; Arlinghaus RB
Cancer Res; 1996 Nov; 56(22):5120-4. PubMed ID: 8912843
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the Bcr-Abl oncoprotein by Bcr requires phosphoserine 354.
Hawk N; Sun T; Xie S; Wang Y; Wu Y; Liu J; Arlinghaus RB
Cancer Res; 2002 Jan; 62(2):386-90. PubMed ID: 11809685
[TBL] [Abstract][Full Text] [Related]
3. Bcr and Abl interaction: oncogenic activation of c-Abl by sequestering Bcr.
Ling X; Ma G; Sun T; Liu J; Arlinghaus RB
Cancer Res; 2003 Jan; 63(2):298-303. PubMed ID: 12543778
[TBL] [Abstract][Full Text] [Related]
4. Bcr phosphorylated on tyrosine 177 binds Grb2.
Ma G; Lu D; Wu Y; Liu J; Arlinghaus RB
Oncogene; 1997 May; 14(19):2367-72. PubMed ID: 9178913
[TBL] [Abstract][Full Text] [Related]
5. Tyrosine phosphorylation and activation of focal adhesion kinase (p125FAK) by BCR-ABL oncoprotein.
Gotoh A; Miyazawa K; Ohyashiki K; Tauchi T; Boswell HS; Broxmeyer HE; Toyama K
Exp Hematol; 1995 Oct; 23(11):1153-9. PubMed ID: 7556524
[TBL] [Abstract][Full Text] [Related]
6. BCR-ABL tyrosine kinase is autophosphorylated or transphosphorylates P160 BCR on tyrosine predominantly within the first BCR exon.
Liu J; Campbell M; Guo JQ; Lu D; Xian YM; Andersson BS; Arlinghaus RB
Oncogene; 1993 Jan; 8(1):101-9. PubMed ID: 8423987
[TBL] [Abstract][Full Text] [Related]
7. Preparation and application of antibodies to phosphoamino acid sequences.
Sun T; Campbell M; Gordon W; Arlinghaus RB
Biopolymers; 2001; 60(1):61-75. PubMed ID: 11376433
[TBL] [Abstract][Full Text] [Related]
8. Identification and characterization of two novel SH2 domain-containing proteins from a yeast two hybrid screen with the ABL tyrosine kinase.
Oda T; Kujovich J; Reis M; Newman B; Druker BJ
Oncogene; 1997 Sep; 15(11):1255-62. PubMed ID: 9315092
[TBL] [Abstract][Full Text] [Related]
9. Bcr: a negative regulator of the Bcr-Abl oncoprotein in leukemia.
Arlinghaus RB
Oncogene; 2002 Dec; 21(56):8560-7. PubMed ID: 12476302
[TBL] [Abstract][Full Text] [Related]
10. Requirement of two specific tyrosine residues for the catalytic activity of Bcr serine/threonine kinase.
Wu Y; Liu J; Arlinghaus RB
Oncogene; 1998 Jan; 16(1):141-6. PubMed ID: 9467953
[TBL] [Abstract][Full Text] [Related]
11. Intrinsic regulation of the interactions between the SH3 domain of p85 subunit of phosphatidylinositol-3 kinase and the protein network of BCR/ABL oncogenic tyrosine kinase.
Ren SY; Xue F; Feng J; Skorski T
Exp Hematol; 2005 Oct; 33(10):1222-8. PubMed ID: 16219545
[TBL] [Abstract][Full Text] [Related]
12. Bcr: a negative regulator of the Bcr-Abl oncoprotein.
Wu Y; Ma G; Lu D; Lin F; Xu HJ; Liu J; Arlinghaus RB
Oncogene; 1999 Aug; 18(31):4416-24. PubMed ID: 10442632
[TBL] [Abstract][Full Text] [Related]
13. BCR-ABL-induced oncogenesis is mediated by direct interaction with the SH2 domain of the GRB-2 adaptor protein.
Pendergast AM; Quilliam LA; Cripe LD; Bassing CH; Dai Z; Li N; Batzer A; Rabun KM; Der CJ; Schlessinger J
Cell; 1993 Oct; 75(1):175-85. PubMed ID: 8402896
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of Abl tyrosine kinase enhances nerve growth factor-mediated signaling in Bcr-Abl transformed cells via the alteration of signaling complex and the receptor turnover.
Koch A; Scherr M; Breyer B; Mancini A; Kardinal C; Battmer K; Eder M; Tamura T
Oncogene; 2008 Aug; 27(34):4678-89. PubMed ID: 18427551
[TBL] [Abstract][Full Text] [Related]
15. Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).
Beran M; Cao X; Estrov Z; Jeha S; Jin G; O'Brien S; Talpaz M; Arlinghaus RB; Lydon NB; Kantarjian H
Clin Cancer Res; 1998 Jul; 4(7):1661-72. PubMed ID: 9676840
[TBL] [Abstract][Full Text] [Related]
16. Selective pyrrolo-pyrimidine inhibitors reveal a necessary role for Src family kinases in Bcr-Abl signal transduction and oncogenesis.
Wilson MB; Schreiner SJ; Choi HJ; Kamens J; Smithgall TE
Oncogene; 2002 Nov; 21(53):8075-88. PubMed ID: 12444544
[TBL] [Abstract][Full Text] [Related]
17. Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
Hantschel O; Superti-Furga G
Nat Rev Mol Cell Biol; 2004 Jan; 5(1):33-44. PubMed ID: 14708008
[TBL] [Abstract][Full Text] [Related]
18. Peptide containing the BCR oligomerization domain (AA 1-160) reverses the transformed phenotype of p210bcr-abl positive 32D myeloid leukemia cells.
Guo XY; Cuillerot JM; Wang T; Wu Y; Arlinghaus R; Claxton D; Bachier C; Greenberger J; Colombowala I; Deisseroth AB
Oncogene; 1998 Aug; 17(7):825-33. PubMed ID: 9779999
[TBL] [Abstract][Full Text] [Related]
19. Protein kinase CK2alpha is a target for the Abl and Bcr-Abl tyrosine kinases.
Hériché JK; Chambaz EM
Oncogene; 1998 Jul; 17(1):13-8. PubMed ID: 9671309
[TBL] [Abstract][Full Text] [Related]
20. Use of a temperature-sensitive mutant to define the biological effects of the p210BCR-ABL tyrosine kinase on proliferation of a factor-dependent murine myeloid cell line.
Carlesso N; Griffin JD; Druker BJ
Oncogene; 1994 Jan; 9(1):149-56. PubMed ID: 8302574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
